Compare Stocks: BLRX, HOWL, TVGN, and MGX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BLRX BioLineRx	$2.21 +0.2%	$2.62	$2.15 ▼ $4.50	$10.98M	1.61	27,744 shs	8,926 shs
HOWL Werewolf Therapeutics	$0.91 -1.1%	$0.77	$0.27 ▼ $1.94	$44.23M	0.51	2.61 million shs	77,305 shs
MGX Metagenomi	$0.99 +0.6%	$1.17	$0.96 ▼ $3.95	$37.44M	0.69	195,579 shs	248,090 shs
TVGN Tevogen Bio	$6.55 +0.9%	$7.00	$3.64 ▼ $39.00	$42.64M	0.19	21,774 shs	416 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BLRX BioLineRx	-4.14%	-6.38%	-17.60%	-27.39%	-50.45%
HOWL Werewolf Therapeutics	-0.21%	-0.24%	-4.78%	+143.09%	-52.33%
MGX Metagenomi	-4.40%	-7.10%	-15.84%	-21.85%	-66.62%
TVGN Tevogen Bio	+3.70%	+1.66%	-8.31%	+19.33%	-81.86%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BLRX BioLineRx	$2.21 +0.2%	$2.62	$2.15 ▼ $4.50	$10.98M	1.61	27,744 shs	8,926 shs
HOWL Werewolf Therapeutics	$0.91 -1.1%	$0.77	$0.27 ▼ $1.94	$44.23M	0.51	2.61 million shs	77,305 shs
MGX Metagenomi	$0.99 +0.6%	$1.17	$0.96 ▼ $3.95	$37.44M	0.69	195,579 shs	248,090 shs
TVGN Tevogen Bio	$6.55 +0.9%	$7.00	$3.64 ▼ $39.00	$42.64M	0.19	21,774 shs	416 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BLRX BioLineRx	-4.14%	-6.38%	-17.60%	-27.39%	-50.45%
HOWL Werewolf Therapeutics	-0.21%	-0.24%	-4.78%	+143.09%	-52.33%
MGX Metagenomi	-4.40%	-7.10%	-15.84%	-21.85%	-66.62%
TVGN Tevogen Bio	+3.70%	+1.66%	-8.31%	+19.33%	-81.86%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BLRX BioLineRx	1.00	Sell	N/A	N/A
HOWL Werewolf Therapeutics	2.43	Hold	$4.00	339.56% Upside
MGX Metagenomi	2.75	Moderate Buy	$6.00	505.45% Upside
TVGN Tevogen Bio	1.50	Reduce	$100.00	1,426.72% Upside

Current Analyst Ratings Breakdown

Latest BLRX, HOWL, TVGN, and MGX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/5/2026	HOWL Werewolf Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
9/22/2026	MGX Metagenomi	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/10/2026	HOWL Werewolf Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/9/2026	MGX Metagenomi	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/26/2026	MGX Metagenomi	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/12/2026	MGX Metagenomi	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/11/2026	MGX Metagenomi	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$7.00
7/23/2026	MGX Metagenomi	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/17/2026	BLRX BioLineRx	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	TVGN Tevogen Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/8/2026	MGX Metagenomi	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 10/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BLRX BioLineRx	$1.18M	9.31	N/A	N/A	$5.36 per share	0.41
HOWL Werewolf Therapeutics	$1.88M	23.52	N/A	N/A	$0.51 per share	1.78
MGX Metagenomi	$25.21M	1.49	N/A	N/A	$4.22 per share	0.23
TVGN Tevogen Bio	N/A	N/A	N/A	N/A	($211.84) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BLRX BioLineRx	-$1.17M	-$1.69	N/A	N/A	N/A	-502.08%	-34.80%	-18.27%	11/23/2026 (Estimated)
HOWL Werewolf Therapeutics	-$60.82M	-$0.76	N/A	N/A	N/A	N/A	-166.99%	-59.88%	11/3/2026 (Estimated)
MGX Metagenomi	-$87.87M	-$2.49	N/A	N/A	N/A	-384.61%	-63.65%	-44.52%	11/10/2026 (Estimated)
TVGN Tevogen Bio	-$26.27M	-$4.63	N/A	N/A	N/A	N/A	N/A	-468.32%	11/13/2026 (Estimated)

Latest BLRX, HOWL, TVGN, and MGX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/3/2026	Q3 2026	HOWL Werewolf Therapeutics	-$0.22	N/A	N/A	N/A	$18.31 million	N/A
8/28/2026	Q2 2026	BLRX BioLineRx	-$0.15	-$0.77	-$0.62	N/A	$0.50 million	$0.29 million
8/14/2026	Q2 2026	TVGN Tevogen Bio	-$2.53	-$1.52	+$1.01	-$1.52	N/A	N/A
8/10/2026	Q2 2026	MGX Metagenomi	-$0.5531	-$0.73	-$0.1769	-$0.73	$3.01 million	($0.26) million
7/31/2026	Q2 2026	HOWL Werewolf Therapeutics	-$0.28	$0.08	+$0.36	$0.08	$21.00 million	$21.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BLRX BioLineRx	N/A	N/A	N/A	N/A	N/A
HOWL Werewolf Therapeutics	N/A	N/A	N/A	N/A	N/A
MGX Metagenomi	N/A	N/A	N/A	N/A	N/A
TVGN Tevogen Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BLRX BioLineRx	0.13	1.20	1.04
HOWL Werewolf Therapeutics	N/A	2.91	2.91
MGX Metagenomi	N/A	4.50	4.50
TVGN Tevogen Bio	N/A	0.33	0.33

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BLRX BioLineRx	1.56%
HOWL Werewolf Therapeutics	64.84%
MGX Metagenomi	N/A
TVGN Tevogen Bio	N/A

Insider Ownership

Company	Insider Ownership
BLRX BioLineRx	1.10%
HOWL Werewolf Therapeutics	23.60%
MGX Metagenomi	12.50%
TVGN Tevogen Bio	65.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BLRX BioLineRx	24	4.98 million	4.92 million	Optionable
HOWL Werewolf Therapeutics	14	48.60 million	37.13 million	Optionable
MGX Metagenomi	113	37.78 million	33.06 million	N/A
TVGN Tevogen Bio	18	6.51 million	2.24 million	N/A

BLRX, HOWL, TVGN, and MGX Headlines

Recent News About These Companies

Tevogen Regains Compliance with Nasdaq Global Market Continued Listing Requirements

September 30, 2026 | globenewswire.com

Tevogen Bio Holdings Rebrands as Tevogen Inc.

July 30, 2026 | tipranks.com

Tevogen Bio Holdings Corporate Event Calendar | NASDAQ:TVGN

July 24, 2026 | benzinga.com

Tevogen Bio Announces 2026 Annual Meeting of Stockholders

July 13, 2026 | globenewswire.com

Tevogen Bio Inc: Tevogen Announces Formation of a Healthcare Services Initiative

June 10, 2026 | finanznachrichten.de

Tevogen Bio Holdings Inc. Announces William Keane as Interim Head of New Healthcare Services Initiative, Exploring MSO and CRO Acquisitions

June 9, 2026 | quiverquant.comQ

Tevogen Announces Formation of a Healthcare Services Initiative

June 9, 2026 | globenewswire.com

Tevogen Bio Inc: Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 Million in Combined Annual Revenue

May 28, 2026 | finanznachrichten.de

Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 ...

May 28, 2026 | enidnews.comE

Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 Million in Combined Annual Revenue

May 28, 2026 | globenewswire.com

Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Management Services ...

May 21, 2026 | caledonianrecord.comC

Tevogen Bio Holdings Inc. Signs Non-Binding Letter of Intent to Explore Strategic Healthcare Transaction

May 21, 2026 | quiverquant.comQ

Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Management Services Organization

May 21, 2026 | globenewswire.com

Tevogen Bio Holdings Inc. Reports Significant Operational Improvements and Strategic Growth Initiatives

May 18, 2026 | quiverquant.comQ

Letter to Shareholders from CEO Dr. Ryan Saadi

May 18, 2026 | globenewswire.com

Tevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest ...

May 12, 2026 | caledonianrecord.comC

Tevogen Bio Holdings Inc. Secures $3 Million PIPE Financing from The Patel Family, LLP

May 12, 2026 | quiverquant.comQ

Tevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest Market Close

May 12, 2026 | globenewswire.com

Tevogen (TVGN) Soars 11% as Firm Gears Up for AI Training Commercialization

May 5, 2026 | finance.yahoo.com

Tevogen.AI Nears Completion of PredicTcell™ Training; Initiates Commercial Readiness and Debuts Internal Application Portal

April 27, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BLRX, HOWL, TVGN, and MGX Company Descriptions

BioLineRx NASDAQ:BLRX

$2.20 +0.01 (+0.23%)

As of 12:56 PM Eastern

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

Werewolf Therapeutics NASDAQ:HOWL

$0.91 -0.01 (-1.10%)

As of 12:56 PM Eastern

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.

Metagenomi NASDAQ:MGX

$0.99 +0.01 (+0.64%)

As of 12:56 PM Eastern

Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.

Tevogen Bio NASDAQ:TVGN

$6.55 +0.06 (+0.92%)

As of 12:49 PM Eastern

Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BLRX, HOWL, TVGN, and MGX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BLRX, HOWL, TVGN, and MGX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BLRX, HOWL, TVGN, and MGX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BLRX, HOWL, TVGN, and MGX Company Descriptions

BioLineRx NASDAQ:BLRX

Werewolf Therapeutics NASDAQ:HOWL

Metagenomi NASDAQ:MGX

Tevogen Bio NASDAQ:TVGN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BLRX, HOWL, TVGN, and MGX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BLRX, HOWL, TVGN, and MGX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BLRX, HOWL, TVGN, and MGX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BLRX, HOWL, TVGN, and MGX Company Descriptions

BioLineRx NASDAQ:BLRX

Werewolf Therapeutics NASDAQ:HOWL

Metagenomi NASDAQ:MGX

Tevogen Bio NASDAQ:TVGN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools